Abstract
A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity. m-AMSA has little activity in patients with gastric adenocarcinoma.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Aminoacridines / adverse effects
-
Aminoacridines / therapeutic use*
-
Amsacrine
-
Anemia / chemically induced
-
Antineoplastic Agents / therapeutic use*
-
Drug Evaluation
-
Humans
-
Leukopenia / chemically induced
-
Stomach Neoplasms / drug therapy*
Substances
-
Aminoacridines
-
Antineoplastic Agents
-
Amsacrine